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Most cancer patients are treated with some combination of surgery, radiation, and chemotherapy. Despite recent advances in local
therapywithcurativeintent,chemotherapeutictreatmentsformetastaticdiseaseoftenremainunsatisfyingduetoseveresideeﬀects
and incomplete long-term remission. Therefore, the evaluation of novel therapeutic options is of great interest. Conventional,
along with newer treatment strategies target the immune system that suppresses genitourinary (GU) malignancies. Metastatic
renal cell carcinoma and non-muscle-invasive bladder caner represent the most immune-responsive types of all human cancer.
This review examines the rationale and emerging evidence supporting the anticancer activity of immunotherapy, against GU
malignancies.
1.Introduction
The immune system is composed of two major subdivisions
the innate immune system and the adaptive immune system.
The innate immune system, comprised of cytokines, macro-
phages, and NK cells is rapidly responsive, while the adaptive
system is antigen speciﬁc and relatively slow to develop.
On the other hand, cellular immune responses including
macrophages and T cell are involved in regulating malignan-
cies. Immunotherapy using activated mononuclear cells is a
way to harness the adaptive immune response, which is
comprised of the antigen-presenting cells (APCs) including
DCs and CD4+ and CD8+ T cells to ﬁght malignancies. The
APCs activate T cells by processing antigens and present
them to T-cell receptors (TCRs) in the context of the MHC
restriction, while CD4+ T cells include both helper and
regulatory T cells (TREG).
Humoral immune responses are usually thought to play
animportantroleininﬂammation,whichischaracterizedby
edema and the recruitment of phagocytic cells. Also, hu-
moral immune responses including antibody are involved in
regulating malignancies. Actually, these humoral factors are
found in serum in patients with malignancies, or they are
formed at the site of tumorigenesis.
Immunological treatment strategies for cancer fall into
two distinctive categories, namely, speciﬁc and nonspeciﬁc
immunotherapy. Nonspeciﬁc immunotherapy induces in-
ﬂammation or otherwise ampliﬁes an already present im-
mune response, for example, IFN, IL-2, and bacillus Calmet-
te-Guerin (BCG). For decades urologists have successfully
usednonspeciﬁcimmunotherapyinthebattleagainstcancer.
BCG in non-muscle-invasive bladder cancer is standard pri-
mary therapy, and IL-2 in renal cell carcinoma is adjunc-
tive therapy. In contrast, speciﬁc immunotherapy requires
tumor-speciﬁc antigen recognition by T cells. Speciﬁc
immunotherapy makes use of antigen-speciﬁc T lympho-
cytes or antibodies produced by B lymphocytes. Recently,
prostate cancer vaccines have attempted to induce cancer-
speciﬁcsystemicimmuneresponsesandrepresentanewclass
of targeted therapies. Several immunotherapeutic strategies
eﬀective against prostate, bladder, or renal cancer in animal
models are under clinical investigation for their eﬃcacy
against human GU malignancies. In addition to existing
therapies, novel approaches that attempt to exploit the
immune system ability to identify, target, and eradicate GU
malignancies are now being developed. This review high-
lights current immunotherapy strategies that may prove to
be successful treatments for GU malignancies.2 Journal of Oncology
2.Renal CellCarcinoma
2.1. General Epidemiology and Disease Burden. Kidney can-
cer is the tenth leading cause of cancer deaths in males in the
United States [1], and death rates of kidney cancer are the
highestamongAmericanIndians/AlaskanNatives.InEurope
approximately 14,000 people die annually of renal tumors
with an estimated 27,000 new cases per year. About two-
thirds of all patients present with localized disease, which
can mostly be cured by radical or partial nephrectomy with a
60% to 70% 5-year survival rate. A third of patients present
with metastatic disease and have a life expectancy of less than
12 months. The prognosis in patients with metastatic renal
cell carcinoma (mRCC) is poor with approximately 1-year
median survivaland a10% to 20%2-yearsurvivalrate[2,3].
This is largely due to the absence of eﬀective chemotherapy
agents and the limited usefulness of radiation therapy for
mRCC.
2.2.AssociationwithObesity. Severalriskfactorsfordevelop-
ing RCC have been reported, including smoking, hyperten-
sion, and obesity [4, 5]. The association to obesity is widely
acceptedandhasbeenreportedconsistentlyinseveralstudies
[6–8] .T h e r ei se v i d e n c eo fe l e v a t e dl e v e l so fn u m e r o u s
proinﬂammatory molecules in the blood of obese [9–11].
Also, the association between obesity and kidney disease is
described, suggesting that inﬂammation could play an im-
portant role in the pathogenic mechanism of renal injury
in obese patients [12, 13]. Indeed, C-reactive protein (CRP)
represents a promising prognostic variable in patients with
RCC [14–18].
2.3. Leptin and Its Role in RCC Development. Potential bi-
ologic mechanisms that have been hypothesized, including
higher levels of estrogen and insulin, higher concentrations
of growth factors in adipose tissue, and immune dysfunction
[5]. Spyridopoulos et al. reported that levels of leptin, which
is produced in adipose tissue and plays a modulatory role
between metabolism and immunity, were inversely associ-
ated with RCC risk [19]. Adipose tissue produces a variety
of inﬂammatory factors, including leptin, adiponectin, as
well as cytokines. Indeed, plasma leptin levels are strongly
associated with total adipose tissue mass [20–23]. The exact
mechanism by which obesity, a state of chronic, slightly
systemic inﬂammation, is a risk factor for developing RCC
still remains unknown. Not only is plasma leptin increased
in obese subjects, but leptin is decreased in adipose tissue
mass induced by exercise [24] and anorexia nervosa [25].
Leptin also plays an antitumor eﬀect through induction of
NK cells proliferation and activation. Interestingly, it is re-
ported that excess risk for developing RCC was observed
among patients with low plasma levels of leptin, after adjust-
ing for potential confounding factors, such as central obesity,
DM and adiponectin [19]. Given the immunogenic nature
of RCC and the role of leptin in the regulation of immuno-
competence, crosstalk between lymphocytes and adipocytes
may contribute to immune regulation in patients with RCC,
contributing to tumor development.
2.4. Conventional Immunotherapy for Metastatic RCC. In ad-
dition to drugs already used in clinical practice, novel drugs
are already under evaluation in clinical trials (Table 1). Im-
munotherapy for mRCC mainly involves the direct adminis-
tration of eﬀector molecules or cells to a patient and requires
no relationship with the host immune system. Cytokines can
indirectlyaﬀecttumorgrowthbyinducingcytolyticTcellsor
by acting directly on tumor cells. Interferon (IFN)-alfa and
IL-2 are widely studied examples of passive immunotherapy
for mRCC. Since IL-2 has believed to have no direct impact
on mRCC cells, the eﬀe c to fI L - 2o nm R C Ci sb e l i e v e dt o
be its ability to expand T-cell populations with antitumor
activity [26]. If, however, the cytokine activate’s the host
immune system, these cytokine therapies are considered to
be active immunotherapy. Evidence from knockout mice
suggests that IL-2 is crucial for the homeostasis and function
of CD4+ CD25+ regulatory T cells in vivo [27]. Although the
response rate in patients with mRCC treated with IL-2 varies
between 10% and 20%, some responses are durable. High-
dose IL-2 appears to be able to cure a small percentage of
highly selected patients [28].
2.5. Combination Immunotherapy. Some studies suggest that
combination therapies involving IL-2 combined with addi-
tionalcytokinesmaybemoreeﬀectivethanIL-2alone.Akaza
et al. investigated the eﬃcacy of combination therapy of low-
dose IL-2 and IFN-alpha. In the 46 patients evaluated in
Phase 1 and Phase 2, the response rate was 26.1% (12 of 46
patients), being highest in 38.7% (12 of 31 patients) of those
who were nephrectomized, and with only lung metastases.
Passalacqua et al. conducted Phase 3, randomised, multi-
centre trial of maintenance immunotherapy with low-dose
IL-2 and IFN-alfa for mRCC patients [29]. Maintenance
immunotherapy after disease progression was found to be
feasible but did not signiﬁcantly increase OS [29]. Cytokine
therapy may be used in combination with chemotherapy as
adjuvant therapy.
Oblimersenisan18-base oligodeoxynucleotide encoding
antisense to the gene for bcl-2, an antiapoptotic protein that
is upregulated in renal and other cancers. Margoline et al.
evaluated the combination of oblimersen with IFN-alfa in
mRCC [30]. They found that only 1 patient of 23 patients
enrolled in the study had a partial response lasting 2.5
months, concluding oblimersen given in the dose and sched-
ule used with IFN-alfa does not appear suﬃciently active to
warrant further study in mRCC [30].
2.6. Cytokines, Immunomodulators, and DCs. Another cy-
tokine, IL-12, induces the diﬀerentiation of T cells into a
T-helper-1(Th1) phenotype. CD8+ population of the Th1
phenotype is considered to be cytotoxic T lymphocyte (CTL)
which is highly cytolytic. In a murine model combination
therapywithIL-12andIL-2causedtheregressionofprimary
and metastatic disease with signiﬁcantly better results than
solo treatment with either agent. Granulocyte-macrophage
colony-stimulating factor (GM-CSF) has received greater
focus from the therapeutic perspective because of its ability
to activate monocyte and macrophages, which can directly
mediate antitumor activity through activated macrophagesJournal of Oncology 3
Table 1: Summary of immunotherapies and targeted agents in mRCC.
Agent Class Mechanism of action Stage of treatment PFS (months)
IL-2 Cytokine Modulation of the host’s immune response First line for selected patients
IFN-alfa Cytokine Activate NK cells and macrophages Second line 3.1–5.4
IFN-alfa + IL-2 Cytokine Modulation of the host’s immune response First line for selected patients
IL-12 Cytokine Modulation of the host’s immune response Phase II
IL-2 + GM-CSF + IFN-alfa Cytokine Modulation of the host’s immune response Phase II 6
Sunitinib Small molecule TKI of VEGFR, PDGFR First line/second line 11.1
Sorafenib Small molecule TKI of VEGFR, PDGFR, Ras First line/second line 5.5
Temsirolimus Small molecule mTOR inhibitor First line (used for poor risk) 5.5
Everolimus Small molecule mTOR inhibitor Second line (used for TKI/IFN
refractory mRCC)
Pazopanib Small molecule TKI of VEGFR, PDGFR Phase II, III
Vatalanib Small molecule TKI of VEGFR, PDGFR Phase I
Imatinib Small molecule TKI of PDGR Phase II
Geﬁtinib Small molecule TKI of EGFR Phase II
Erlotinib Small molecule TKI of EGFR Phase II
Bortezomib Small molecule 26S proteasome inhibitor Phase II
Lapatinib Small molecule TKI of EGFR/Erb/2 Phase II, III
Oblimersen Oligo Antisense oligo Phase II
Tumor vaccination Protein Tumor-speciﬁc T-cell response Phase II
Bevacizumab (+ IFN-alfa) Mab Antibody to VEGF First line 8.5–10.2
Cetuximab Mab Antibody to EGFR Phase II
VEGF-trap Mab Antibody to VEGF Phase I, II
G250 Mab Antibody to CA IX Phase II
Abbreviations: TKI; tyrosine kinase inhibitor, IFN; interferon, mRCC; metastatic renal cell carcinoma, NK; natural killer, Mab; monoclonal antibody.
to release TNF-alfa. Garcia et al. conducted Phase 2 trial of
subcutaneous IL-2, GM-CSF, and IFN-alfa in patients with
mRCC [31]. The overall response rate was 20% (one com-
plete response and 11 partial responses of 60 patients), and
the median progression-free survival and overall survival
were 6.0 and 23.4 months, respectively, suggesting the
potent eﬃcacy. GM-CSF also promotes dendritic cell (DC)
diﬀerentiation and survival. Flt3 ligand (Flt3-L), a member
of a growth factors that stimulate the proliferation of hema-
topoietic stem cells, is being tested for its ability to increase
DCnumbers[32].Flt3hasalsobeentestedinmRCCpatients
inclinicaltrials,andresultsdemonstratedthatalthoughFlt3-
L is capable of inducing the expansion of circulating DCs in
patients with mRCC, it lacked relevant clinical activity at the
doses and schedules examined [33, 34].
2.7. Tumor Vaccine. Active speciﬁc immunotherapy includes
the vaccination of patients virtually to induce long-lasting,
tumor-speciﬁcimmunitywhichiscapableofrejectingcancer
cells as well as inducing safe and protective immunological
memory. Autologous tumor cell vaccines are being used in
an attempt to induce tumor-speciﬁc immune responses in
mRCC.Thesevaccinesincludegeneticallyalteredtumorcells
to enhance the immunogenicity of the tumor cells, thereby,
inducing a tumor-speciﬁc T-cell response. Schendel et al.
tested the possible application of vaccination with allogeneic
tumor cells [35]. In the study, a human RCC cell line was
genetically modiﬁed by retroviral transduction to express
the costimulatory molecule CD80. It was possible to isolate
CTL clones that were able to accomplish tumor lyses that
expressed all of the corresponding allospeciﬁcities, demon-
strating that the induction of allospeciﬁc responses did not
hinder the development of tumor-associated CTLs in vitro.
In practice, Lemoine et al. conducted Phase 2 trial to check
whether systemic administration of IL-2 or infusion of DCs
loadedwithtumorextractscouldleadtosomeresponserates
with concomitant survival improvements [36]. No adverse
eﬀect due to the vaccinations was observed in 5 patients
enrolled. A speciﬁc immune response against autologous
tumor cells was observed in the 2 of 5 patients who com-
pleted the treatment. A transient and massive increase of
circulating natural regulatory T-cells was evidenced in 3
patients following IL-2 administration [36]. These results
may support the use of modiﬁed allogeneic tumor cells for
the vaccination of partial MHC-matched patients with RCC.
2.8. Molecular Targeted Therapy. Newer studies suggest that
targeted therapy for mRCC, including sunitinib, sorafenib,
temsirolimus, everolimus, or combined bevacizumab and
IFN-alfa, has proved eﬃcacious as ﬁrst- or second-line
treatmentalthoughtheyhavenotyetshownastatisticallysig-
niﬁcant survival beneﬁt except for temsirolimus in the high-
risk mRCC subgroup. Thus, there is still an urgent need to
improve pharmacotherapy for mRCC. Cho et al., conducted4 Journal of Oncology
a retrospective analysis of the tolerability and eﬃcacy of IL-
2 therapy in patients who had previously received VEGF-
targeted therapy including tyrosine-kinase inhibitor (TKI)
[37]. No patients achieved a partial or complete response
to therapy, and the incidence of severe cardiac toxicities in
patients receiving prior TKI reached 40%, concluding that
the assumption that IL-2 therapy can be safely administered
after TKI therapy may not be valid [37]. Gollob et al. tested
the activity and tolerability of TKI sorafenib administered
with IFN-alpha-2b as ﬁrst- or second-line therapy in mRCC
patients [38]. In this Phase 2 study, the response rate was
33% (95% CI, 19% to 49%; 13 of 40 patients), including
28% partial responses (n = 11) and 5% complete responses
(n = 2), with the median duration of response 12 months.
Especially, responses were seen in treatment-naive and IL-2
treatedpatients[38].Accumulatingdatabylargercohortwill
further the rationale for new drugs based on combination
therapy with immunotherapy to enhance the eﬀect of
immunomodulators on patient survival.
2.9. Bladder Cancer. B l a d d e rc a n c e ri st h e4 t hm o s tc o m m o n
genitourinary cancer in men and the 7th in women with
an incidence of more than 70,000 new cases in the United
States in 2010 [1]. At presentation up roughly 80% of pa-
tients are found to have non-muscle-invasive bladder cancer
(NMIBC), which is disease conﬁned to the superﬁcial layer
of the bladder (mucosa, lamina propria), speciﬁcally Ta,
T1 or carcinoma in situ (CIS) [39]. Approximately half of
NMIBC is at risk for disease recurrence and progression.
Therefore, they require adjuvant intravesical treatment after
tumor resection. Currently the gold standard treatment for
noninvasive bladder cancer is BCG instillation into the
bladder, which is now the most commonly used intravesical
treatment for high-risk NMIBC endorsed in European
Association of Urology and American Urological Association
practice guidelines [40–42]. Virtually it is believed that there
exists a host-immune escape associated with bladder cancer.
Hence, the generation of a localized immune response in
the bladder by the intravesical administration of live BCG
may transiently restore impaired immune system in the
peritumoral bladder wall, so that BCG can elicit the tumor
rejection. Some studies were conducted to evaluate the
mechanism of binding of BCG within the bladder. In a
mouse model, it is known that BCG attaches to the bladder
wall only in areas with urothelial damage [43]. Studies per-
formed using puriﬁed extracellular matrix proteins to iden-
tify the proteins responsible for attachment suggest that
BCG preferentially attaches to surfaces coated with puriﬁed
ﬁbronectin (FN) and to a lesser extent to other puriﬁed pro-
teins including laminin, collagen, or ﬁbrinogen [43]. Immu-
nological aspects of BCG therapy for NMIBC are related to
the presence of delayed-type hypersensitivity. Inﬂammatory
response occurs after BCG instillation in to the bladder,
which is characterized by an induction of leukocyte sub-
populations, such as granulocytes, CD4+ and CD8+ T
cells, NK cells, B lymphocytes, activated lymphocytes, and
dendritic cells. Following this cellular recruitment, cytokines
characterized as part of the Th1 and Th2 immune response
accumulate [44]. Cytokines which are in charge of the
antitumor response are essentially those related to Th1,
including IL-2, IL-12, TNF-alfa, and IFN-gamma [44].
Intravesical BCG, a nonspeciﬁc active immunotherapy, has
been used in the intravesical treatment of NMIBC for about
35 years. Despite an initial treatment success many patients
with NMIBC eventually have recurrence after intravesical
BCG treatments. Patients with CIS are more at risk for
recurrence or advanced disease. Despite BCG treatment 42%
to 83% of patients with CIS associate with papillary NMIBC
and 20% to 34% with primary CIS experience progression
to muscle invasive disease [45]. Although BCG is an eﬀective
adjuvanttreatmentforpreventingbladdercancerrecurrence,
it is associated with a high incidence of adverse eﬀects, which
include nausea, vomiting, weight loss, anorexia, bladder ir-
ritation, dysuria, polyuria, hematuria, cystitis, urinary ur-
gency, urinary tract infections, ﬂu-like syndrome, and so on
[46, 47]. No consensus has been reached about the optimal
dose for BCG therapy nor about how the toxicity of BCG
treatment can be reduced. Variations in the reported fre-
quency of BCG-associated adverse events could be caused by
variations in the dose of BCG used. Therefore, dose reduc-
tions may be a potential option for the prevention of BCG-
associated adverse events, particularly for those patients
known to be intolerant to standard-dose BCG. Mack and
Frick reported the results of a Phase 2 study with low-dose
BCG therapy in high-risk NMIBC and concluded that low-
dose BCG therapy is an eﬀective treatment in high-risk T1
bladder cancer, especially with maintenance therapy to pre-
vent progression and recurrence [48].Long-termoutcomeof
a low-dose intravesical BCG therapy for CIS of the bladder is
reported [49].Completeresponsewasachievedin84%ofthe
patients, in whom the recurrence-free rate was 72.4% after 3
years and 61.9% after 5 years. The median CR duration was
37.5 months, suggesting the eﬃcacy and safety of low-dose
BCG therapy for CIS of the bladder. A number of unresolved
questions surround the BCG host interplay which may be
characterized by a number of diﬀerent strains of BCG. BCG
daughter strains are divided into the early strains: Japan,
Birkhaug, Russia and Brazil, which were brought to each
country between 1924 and 1926, and the late strains: Pasteur,
Danish, Glaxo and Connaught, which were obtained after
1931. Although all of these strains are descendants of the
original M. Bovis isolate, subsequent passage under diﬀerent
conditions has resulted in a variety of strains with unique
genetic alterations. Diﬀerences of antitumor eﬀect between
thestrains,ifany,remainunknown.Onlyafewstudiesreport
the eﬃcacy of diﬀerent strain. Dutch South East Cooperative
Urological Group evaluated BCG-Tice versus BCG-RIVM
in 469 patients with pTa/pT1 carcinoma and found that
there were no statistical diﬀerences were observed in toxicity
between the two strains of BCG [50]. Connaught (Canada),
Pasteur(France),ArmandFrappier(Canada),andTokyo172
(Japan) were employed and studied for the eﬃcacy in low-
dose regimens [51–53]. Lamm reported that there were
diﬀerences in complication rates with various BCG strains
[47,54].Theincidenceofcystitislikesymptoms,haematuria,
and fever in our series was 64%, 40%, and 20%, respectively
[47, 54]. Irie et al. prospectively evaluated the eﬃcacy
and adverse events of low dose (40mg) Tokyo 172 strain.Journal of Oncology 5
There was no signiﬁcant diﬀerence in tumor recurrence rate
between the low dose (40mg) group and the standard dose
(80mg) group [55]. Similarly, Takashi et al. reported that
the dose (40 versus 80mg) of BCG was not a signiﬁcant
determinant for CR in patients with CIS of the bladder [56].
These studies suggest that 40mg would be an adequate dose
for Tokyo 172 strain, and comparable study is possible with
a dose of 40mg. No prospective studies have been conducted
to compare low dose Tokyo 172 strain (40mg) with other
BCG substrains. Side eﬀects are commonly manifested dur-
ing BCG therapy. Delay or interruption of instillation due
to side-eﬀects may actually be detrimental to eﬃcacy. So an
important issue is whether a low-dose regimen can reduce
toxicitywhilemaintainingeﬃcacy.FromaPhaseIIIrandom-
ized trial comparing low-dose versus standard-dose BCG
(Pasteur strain, 75 versus 150mg), Pagano et al. reported
a signiﬁcant decrease in most of the common side eﬀects
(cystitis, fever, haematuria; P<0.05), clarifying the rela-
tionships between dose and toxicity [52]. Studies, however,
provided only short-term followup ranging from months to
two years and data on the long-term condition of bladder
patients originally treated with low-dose BCG is very rare.
Losa et al. retrospectively reviewed 70 consecutive patients
withprimaryorsecondarycarcinomainsituwithorwithout
concomitant solitary or multifocal papillary tumor treated
with weekly instillations of low-dose Pasteur strain for 6
weeks with median followup of 74 months [51]. Mean time
was 18 months (range 6 to 69) to treatment failure and 13
months (range 7 to 53) to progression [51]. They conclude
that low-dose BCG is similarly eﬀective, with a lower in-
cidence of side eﬀects and long-lasting positive outcome.
Similarly, Kamel et al. retrospectively evaluated 74 patients
withG3,T1bladdercancertreatedbya6-weekcourseoflow-
dose Pasteur strain with median followup of 61 months [57].
Median time to treatment failure was 20 months. Regarding
toxicity, irritative symptoms occurred in 24% of patients,
fever in 9%, microscopic hematuria in 14%, which appeared
to be lower when compared with the rates reported for
regular doses of BCG [57].
Usage of low-dose BCG for aggressive bladder cancer is
controversial. Hurle et al. assessed the eﬀectiveness of low-
dose BCG for high-risk T1/G3 bladder cancer patients who
hadweeklyinstillationsoflow-dosePasteurstrainfor6-week
[58].Withamedianfollowupof33months,28of51patients
(54.9%) were disease-free, and the risk of treatment failure
was signiﬁcantly greater for solid than papillary tumors
(P = 0.0006), recurrent than primary tumors (P = 0.0052),
and coexisting carcinoma in situ (P = 0.124) in multivariate
analysis, suggesting that this low-dose Pasteur BCG is eﬀec-
tive in the treatment of high-risk NMIBC, except for some
tumor characteristics, such as solid appearance, coexisting
carcinoma in situ, history of superﬁcial transitional cell
carcinoma,andearlyrelapseaftertheinitialinductioncourse
[58]. In contrast, Herr concluded that patients with highly
malignant bladder cancer would not beneﬁt from a dose
reduction [59]. Now maintenance BCG therapy is proved
to be useful for high-risk NMIBC patients. Although, long-
term tolerance remains an important issue with mainte-
nance schedule. Because complex immunological pathway
contributes to the success of BCG therapy, stratiﬁcation of
the patients by their immunological aspects may help physi-
cians to predict the response to BCG.
3. ProstateCancer
Immunotherapy has also been carried out on other GU ma-
lignancies, except for mRCC and NMIBC, and primarily the
prostate cancer has been a particular focus of immunother-
apy. Despite improvements in surgery or radiotherapy
for localized prostate cancer, 30% will develop metastatic
disease. Once become metastatic, usually to the bone, the
disease is no longer curable and is usually treated with
androgen depletion therapy (ADT). Some studies support
the evidenced that ADT induce an immune response against
the prostate, which includes T-cell inﬁltration of the prostate
and induce thymic regeneration. Disappointingly, over 50%
of these patients treated by ADT progress to castration-
resistant prostate cancer (CRPC) within a median of 18
to 24 months. CRPC remains an incurable disease when
treated with docetaxel-based chemotherapy, and prednisone
currently the only FDA-approved chemotherapeutic agent
for the treatment of CRPC, because docetaxel-prednisone
extended median overall survival modestly to 19 months
and only 20% patients attained 3-year survival based on
the results of two large randomized trials [60, 61]. Several
immunotherapeutic strategies eﬀective against prostate can-
cer in animal models are under clinical investigation for
their eﬃcacy against human CRPC. Cytokines, including IL-
2 and IFN-alfa, which are mainly used in mRCC patients
may also be useful for treating other GU malignancies. In
a pilot study of CRPC involving IL-2 and IFN-alfa admin-
istration, some partial responses and PSA serum level
decreases were reported. In the last 10 years, many cancer
vaccines,tobespeciﬁcactiveimmunotherapyagainstspeciﬁc
tumor-associated antigens, were tried in clinical trials. These
vaccinesincludeDC,wholetumorcell,peptide,viralvectors,
and so on. Although most of these vaccines were not ap-
proved by the US FDA. Most recently, US FDA approval
of 2 immunotherapies including sipuleucel-T (Provenge,
DendreonCorp,WA,USA)andipilimumab(Yervoy,Bristol-
Myers Squibb) [62]. Sipuleucel-T is a novel autologous
dendritic cell-based vaccine, and the tissue-speciﬁc antigen
forimmunization is prostatic acid phosphatase (PAP),which
is expressed in about 95% of prostate tumors, and has highly
speciﬁc expression for prostatic tissue. PAP is linked to GM-
CSF, so that GM-CSF functions to enable eﬃcient GM-CSF-
receptor-mediated uptake of the PAP antigen, resulting in
enhancing its antigenicity and DC-stimulating properties,
moiety and augments the immune response. In a random-
ized crossover trial, 127 previously untreated men with
metastatic CRPC were assigned [63]. The median survival
for sipuleucel-T was signiﬁcantly better than for placebo
(25.9 versus 21.4 months, P = 0.01) and 3-year survival was
prolonged with sipuleucel-T (34 versus 11%, P = 0.0046).
Also, in the double-blind, placebo-controlled, multicenter
Phase 3 trial, there was a relative reduction of 22% in the
risk of death in the sipuleucel-T group as compared with
the placebo group (P = 0.03), suggesting that sipuleucel-T6 Journal of Oncology
prolongs overall survival among men with metastatic CRPC
[64]. The activation of negative regulatory signals in T cells
is required to avert an unduly exuberant immune response,
which include cytotoxic T-lymphocyte antigen-4 (CTLA-4)
which is essential for maintaining tolerance for self-antigens.
Ipilimumab, CTLA-4-inhibiting fully human monoclonal
antibodies have demonstrated objective clinical and PSA
responses in advanced CRPC in Phase 1 and Phase 2 trials.
In addition, other novel targets for immunotherapy against
CRPC are likely to expand the therapeutic venue in the near
future. Therefore, the proper sequence of immunotherapy
and appropriate selection of patients will assume beneﬁt.
4. Conclusion
Recent advances in immunotherapy in GU malignancies
haveprovidedinsightintothecomplexityofimmunemanip-
ulation and the promise of improving eﬃcacy and reducing
adverse reactions by better understanding of mechanisms of
immunotherapy. Despite the clinical failures of some immu-
nological treatments, several therapies do warrant further
exploration.
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